VYDURA 75 mg, lyophilizate oral 8 oral lyophilisates
Active ingredients: Rimegepant, Rimegepant sulfate
Commercialized according to BDPMDispensing in France: Prescription only
Lyophilizate8 oral lyophilisatesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- VYDURA 75 mg, lyophilisat oral
- Pharmaceutical form
- lyophilisat
- Route of administration
- orale
- Presentation description
- 8 plaquettes prédécoupées unitaires PVC OPA : polyamide orienté aluminium de 1 lyophilisat(s)
- Marketing authorisation holder
- PFIZER EUROPE MA EEIG (BELGIQUE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 9 Oct 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
65899221CIP73026047CIP133400930260470Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RIMÉGÉPANTlyophilisat | 75 mg · un lyophilisat | FT |
| SULFATE DE RIMÉGÉPANTlyophilisat | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.